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Abstract
Background: Acute delirium is a common complication among critically ill patients.
Besides the manifestation of distressing symptoms, delirium can result in negative patient
outcomes. Several studies show that antipsychotics such as haloperidol are one of the most
commonly used interventions for delirium despite large variability and lower quality of evidence
available to advocate for their use.
Methods: A literature review was conducted to investigate current evidence on the use of
antipsychotic agents for preventing and treating delirium in the intensive care unit.
Discussion: There is conflicting data concerning the prophylaxis and treatment of
delirium in critically ill patients. For prophylaxis with antipsychotics, some studies have shown a
decrease in delirium incidence in post-operative patients with less effect on general ICU
populations. For treatment with antipsychotics, smaller low-powered studies have shown a
decrease in delirium duration while other studies do not show any benefit. High heterogeneity
between studies due to variable study design makes the quality of evidence low. Minimal
conclusions can be drawn from available literature, making it difficult to provide concrete
clinical recommendations.
Conclusion: Given the low quality of evidence, the effectiveness of antipsychotics for
ICU delirium remains uncertain. Antipsychotics should not be implemented for routine use, but
can be considered to treat severe, acute delirium symptoms. Future research is needed to better
establish the benefits and risks associated with antipsychotics and delirium in the ICU.
Introduction
Delirium is a common comorbidity experienced in the intensive care unit (ICU). The
incidence of patients who experience delirium in the ICU has been reported to be around 31%,1
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however some studies report occurrence upwards of 70-80% in older patients.2 Delirium is
defined as a “disturbance in attention (i.e., reduced ability to direct, focus, sustain, and shift
attention) and awareness (reduced orientation to the environment)” per the DSM-V criteria.3 In
addition, these disturbances must be acute in nature and fluctuate throughout the day. Although
delirium cannot be attributed to a concurrent neurocognitive disorder or coma, the etiology must
be due to a consequence of another medical condition, drug intoxication or withdrawal, or
exposure to a toxin.3 Specific clinical manifestations of delirium include hypoactivity (lethargy,
decreased arousal), hyperactivity (agitation, emotional disturbance, refusal to cooperate),
impaired sleep, hallucinations, delusions, and confusion. The pathogenesis of delirium is not well
understood, but it is thought to be multifactorial and includes several theories. The current
understanding of delirium pathophysiology includes neurotransmitter imbalances or alterations
(specifically dopamine and acetylcholine), inflammatory processes (as in post-operative states),
sleep deprivation and polypharmacy.4-6 Likewise, critically ill patients commonly experience
metabolic disturbances, higher levels of pain, frequent interruption of sleep, and common use of
delirium-inducing medications. Known risk factors for developing delirium in the ICU include
increased age, visual and hearing impairment, use of restraints, certain medications, alcohol use,
pre-existing dementia, coma, increased severity of illness, mechanical ventilation, emergency
surgery, trauma, and metabolic acidosis.7-9
Critically ill patients who experience delirium in the ICU are at risk for several adverse
outcomes. Delirium is associated with increased risk of hospital mortality,1 longer hospital and
ICU length of stay, and increased number of days requiring mechanical ventilation.1,10 Patients
with delirium may be more likely to require a tracheostomy and experience increased use of
physical restraints.10 Delirious patients also require higher amounts of medications such as
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benzodiazepines, opioids, and antipsychotics.10 Some sources also report long-term cognitive
disturbances at 12-18 month follow-up as a result of ICU delirium.1,11,12 Although it is difficult to
discern whether some of these adverse outcomes are truly secondary to the delirium itself versus
a reflection of the severity of critical illness that delirious patients typically experience, it is a
common comorbidity that usually requires additional interventions and potentially increased
costs.13 Given the many negative outcomes associated with ICU delirium, it is common practice
to routinely screen for delirium in the ICU using several standardized assessments. The two most
validated and reliable tools include the Confusion Assessment Method for the ICU (CAM-ICU)
and the Intensive Care Delirium Screening checklist (ICDSC).8
Prompt management and prevention of delirium is of great interest to many providers and
researchers in order to prevent adverse outcomes and promote symptomatic relief. Given the
wide etiology, unclear pathogenesis, and several risk factors for delirium in the ICU,
management is typically multifactorial and often challenging. Several preventative measures can
be taken in attempts to decrease risk of delirium development, while treatments for delirium
often aim at increasing time to resolution and/or decreasing delirium symptoms. Much of the
proposed pharmacologic management aims at altering neurotransmitter activity, whether to treat
delirium itself or its associated symptoms. Although there is no drug approved by the FDA
specifically for delirium, several observational studies have shown routine use of medications
among medical providers such as antipsychotics, benzodiazepines, and dexmedetomidine to treat
delirium.11-15 Some studies suggest that antipsychotics such as haloperidol are the most
commonly used medication for managing delirium and delirium-related symptoms among
providers.11,13
Antipsychotics are used mainly to treat neuropsychiatric disorders such as schizophrenia
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and bipolar disorder, and they are currently used off-label for delirium, acute agitation, and
mania. There are two main categories of antipsychotic drugs: first generation (FGA) and second
generation (SGA). The primary mechanism of action for both FGAs and SGAs are blockage of
the dopamine D2 receptors in the central nervous system, however they also have variable
activity at other neurotransmitter receptors. Haloperidol (an FGA) has little effect on histamine
and muscarinic receptors,15 thus, is often used in attempts to provide a small level of dosedependent sedative effect in ICU settings.16 SGAs also block the D2 receptors in the brain but
have high affinity for serotonin receptors.17 As serotonin plays an important role in sleep, some
studies that find positive results using SGAs for delirium propose this serotonin alteration as a
potential mechanism.18 Many SGAs have multi-receptor activity at histamine, muscarinic, and
alpha-adrenergic receptors, resulting in various levels of sedation and anticholinergic effects.19
FGAs and SGAs are thought to have similar efficacy overall in terms of treatment of positive
schizophrenia symptoms such as hallucinations and delusions.20 However, while efficacy has
been more extensively studied in schizophrenia, the data in efficacy studies for antipsychotics in
delirium is lacking and often conflicting.
Since these pharmacologic measures have inadequate or conflicting evidence for use in
the ICU, there is often discrepancy between common clinical practice and research literature.
Contrary to the common utilization of antipsychotics in upwards of 46% of critically ill patients
with delirium,11 the Society of Critical Care Medicine (SCCM) practice guidelines do not
recommend the routine use of medications to treat or prevent delirium.8 Given the lack of
consensus between available literature and the current clinical practice in terms of pharmacologic
management of ICU delirium, this paper will aim to evaluate the current studies available in
regards to effectiveness of antipsychotic drugs in prevention and treatment of delirium. The
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primary outcomes that will be investigated are whether administering antipsychotics results in
reduced incidence and duration of delirium in critically ill patients. Other outcomes such as ICU
and hospital length of stay, mortality, and duration of mechanical ventilation will also be
explored. In addition, this paper will analyze how available literature could be applied to clinical
practice, and whether there are other interventions that may be more beneficial than
antipsychotics in managing delirium.
Background
Antipsychotics for delirium prophylaxis
Several studies have explored the efficacy of administering either first- or secondgeneration antipsychotics as a means of preventing delirium in critically ill and post-operative
patients. Most of the literature has variable and conflicting results. Of the few systematic reviews
and meta-analyses, very few have been able to display strongly positive data on using
antipsychotic prophylaxis. Of the review studies described below, none have found any effect of
haloperidol on factors such as mortality and length of stay in the ICU. Most review studies have
high heterogeneity due to differences in patient populations and study protocols between
randomized controlled trials. In particular, a Cochrane Database Review on prevention of ICU
delirium suggested that the overall evidence for pharmacologic intervention to prevent delirium
is of moderate to low quality, and that the heterogeneity between studies prevents a meaningful
meta-analysis.7 In one systematic review and meta-analysis by Zayed et al,14 six randomized
controlled trials studying haloperidol versus placebo as ICU delirium prophylaxis were analyzed.
The authors concluded that haloperidol has no significant effect on delirium incidence, mortality,
length of stay, or delirium-free days compared to placebo.14 However, high heterogeneity among
studies make it difficult to fully conclude the effects of haloperidol. The studies utilized varying
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doses, routes, and duration of medication as well as varying patient populations. The nonpharmacologic interventions were also not quantified, and the studies used various sedation and
rescue antipsychotic doses.14
Several other reviews and meta-analyses have shown a positive effect of prophylactic
antipsychotics on delirium incidence. A systematic review by Santos et al15 analyzing four
studies was unable to perform a meta-analysis given high heterogeneity between studies.
However, the authors found that two studies12,16 showed prophylactic doses of haloperidol
decreased the incidence of delirium while another two studies17,18 found no change in
incidence.15 One study showed a shorter ICU length of stay,16 however none of the studies
showed a difference in hospital length of stay.12,17,18 As with other review papers, the studies
analyzed varying populations and used different haloperidol doses and schedules. The authors
concluded that while prophylactic haloperidol may reduce delirium incidence, additional studies
with more standardized protocols are required in order to make a recommendation on
prophylactic use.15 A meta-analysis by Gilmore et al19 analyzed five randomized controlled trials
studying antipsychotic prophylaxis in post-operative patients. The analysis showed that
antipsychotics lowered delirium incidence by a 12.7% absolute risk reduction.19 Another metaanalysis by Hirota and Kishi20 looking at prevention of postoperative delirium found that both
olanzapine and risperidone were superior to placebo in preventing delirium while haloperidol did
not alter incidence. However, haloperidol shortened duration of delirium while the other
treatments had no effect on duration. There were no other differences between groups in terms of
delirium duration, length of stay or severity in either of these post-operative studies.19,20
Several randomized controlled trials have studied whether prophylactic antipsychotics
reduce delirium in critically ill patients when compared to placebo. These studies used varying
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doses, schedules, and durations of medication and obtained various results. For example,
Boogaard et al12 administered either 1 mg or 2 mg of intravenous haloperidol three times daily to
delirium-free critically ill adults, starting therapy within 24 hours of ICU admission until ICU
discharge. Page et al17 started therapy within 72 hours of admission for patients requiring
mechanical ventilation (regardless of delirium state), administering 2.5 mg IV haloperidol every
8 hours until ICU discharge or delirium-free for two days. Wang et al16 provided an IV bolus
followed by a 12-hour continuous infusion of haloperidol in patients admitted to ICU after
cardiac surgery. Al-Qadheeb et al18 administered 1 mg IV haloperidol every 6 hours to
mechanically ventilated patients with subsyndromal delirium in efforts to prevent progression to
full delirium. Only one of these studies found a significant difference in delirium outcomes
between groups. Wang et al16 demonstrated among 457 patients, the haloperidol group had lower
incidence of delirium within 7 days post-operatively (15.3% vs. 23.2%, p = 0.031) as well as on
the first and third days after surgery. The occurrence of postoperative delirium in the haloperidol
group was about half as likely to occur as compared with the placebo group (OR 0.574, 95% CI:
0.352–0.937; p = 0.026).16 In addition, the haloperidol group had increased time to onset of
delirium, increased delirium-free days, and shortened ICU length of stay. Neither Page et al,17
Boogaard et al,12 nor Al Qadheeb et al18 found any significant differences between groups in
delirium incidence, duration, delirium-free days, or ICU length of stay when given haloperidol vs
placebo. All four of these studies found no difference in hospital length of stay or
mortality.12,16,17 Page et al19 found that the risk of needing additional open-label antipsychotics
for agitation was lower in the haloperidol group. The haloperidol group also received a reduced
total dose of propofol and fentanyl, but this result was not statistically significant (both p = 0.06).
Additionally, an earlier non-randomized, before and after evaluation study by Boogaard et al21
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administered prophylactic IV haloperidol to patients deemed high risk for delirium per the PREDELIRIC model. They found a reduced delirium incidence in haloperidol group versus control
group (65% vs 75%, p = 0.01).21 Although this trial found benefit to haloperidol prophylaxis, the
non-randomized, retrospective design may not be strong enough to be able to draw clinical
conclusions alone.
Randomized controlled trials have also explored the use of second-generation
antipsychotics for delirium prophylaxis. Larsen et al22 gave elderly patients undergoing joint
replacement surgery 5 mg olanzapine or placebo both immediately pre-operatively and
immediately post-operatively.22 In this 400-patient study, delirium incidence was lower (14.3%
versus 40.2%, p = 0.0001) and time to delirium onset was significantly longer in the olanzapine
group compared to placebo, respectively. Interestingly, the duration of delirium was longer in the
olanzapine group (2.2 versus 1.6 days, p = 0.02). In another study, Prakanrattana and
Prapaitrakool23 administered 1 mg risperidone orally in the ICU after cardiac surgery. The
authors found that the risperidone group had a lower delirium incidence compared to control
(11.1% vs 31.7%, respectively; p = 0.009, NNT 4.85).23 No other differences in outcomes were
statistically significant between groups.
Antipsychotics for delirium treatment
In addition to using antipsychotics as a means to prevent delirium, several studies have
also analyzed their use for treatment of delirium. Many of these studies continue to display high
heterogeneity in study protocol. In two systematic reviews and meta-analyses, there was no
association between using antipsychotics and delirium duration, mortality, or ICU or hospital
length of stay.14,24 Another systematic review suggested that pharmacologic interventions,
including antipsychotics, do not provide any significant reduction in delirium duration or other
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parameters such as length of stay or mortality in available studies.25 In contrast, a meta-analysis
of 15 randomized controlled trials found that antipsychotics had an increased response rate
compared to placebo for delirium treatment (RR = 0.22, NNT = 2).26
Several trials exist that investigate antipsychotics in delirium treatment. In a randomized
controlled trial by Girard et al11, adults with delirium in the ICU per the CAM-ICU assessment
received either placebo, IV haloperidol or IV ziprasidone every 12 hours until delirium subsided.
In this study containing 566 patients, neither haloperidol nor ziprasidone shortened the duration
of delirium. The mortality and ICU length of stay was also similar between groups.11 On the
other hand, Michaud et al27 found positive results on the use of quetiapine in a retrospective
cohort study. Adults with delirium in the ICU per the CAM-ICU assessment (n = 113) received
either quetiapine (n = 52) or no pharmacologic intervention (n = 61) for delirium. The group
whose delirium was treated with quetiapine experienced shorter duration of delirium compared
to those who did not receive pharmacologic intervention. Although the duration was only
decreased by an average of 0.5 days, this decrease was statistically significant (p = 0.04).
However, the duration of delirium was 2.5 days shorter if the patient received the drug within the
first 24 hours of delirium onset versus later than 24 hours. Among patients on mechanical
ventilation, receiving quetiapine within the first 24 hours resulted in shorter time to extubation.27
Another small study on utilization of quetiapine vs placebo for treatment of delirium in critically
ill patients showed positive results, although is limited by a small number of subjects. In this
study by Devlin et al,28 36 patients were randomized to either receive enteral quetiapine every 12
hours versus placebo once diagnosed with delirium. All patients also received as needed IV
haloperidol for delirium and agitation symptoms. The study found that the quetiapine group
spent less time in delirium (36 hours vs. 120 hours, p = 0.006) and agitation (6 hours vs. 36
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hours, p = 0.02).28 Additionally, patients who received quetiapine used significantly less
haloperidol, sedation, and fentanyl.28
Antipsychotics are commonly used to treat specific symptoms of delirium such as
agitation. Page et al17 studied prophylactic use of haloperidol and found that the haloperidol
group had lower levels of agitation (RASS of 2 or greater). They concluded that although
haloperidol did not provide any meaningful delirium prophylaxis, it may be useful in treating
agitation.17 Similarly, haloperidol resulted in decreased agitation compared to placebo in the
randomized controlled trial by Al-Qadheeb et al.18 However, the clinical significance of this
reduced agitation is unknown given this study also found no reduction of delirium or days on
mechanical ventilation despite less agitation.18 In addition, a Cochrane Database Review29 on
using haloperidol for aggression or agitation suggests weak evidence on the topic. The review
found that among nine randomized controlled trials, more patients who were treated with
haloperidol were asleep at 2 hours versus placebo.29 However, these are considered low-quality
studies that make it difficult to make a clinical recommendation.
Risks associated with antipsychotics
Antipsychotic drugs have several adverse effects that are important to consider when
selecting patients to receive this therapy. Some of the major adverse effects include
extrapyramidal side effects (EPS), adverse cardiovascular events, metabolic side effects,
sedation, and anticholinergic effects. In the short term and intensive care setting, the most
concerning acute side effects include QTc prolongation, orthostatic hypotension, sedation, and
EPS.30 There are differences in side effect profiles between FGAs and SGAs. Haloperidol
(especially in IV form) has a higher association with prolonged QTc interval, and this often
requires frequent electrocardiogram monitoring while receiving therapy.30 FGAs have a higher
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risk of EPS, while SGAs come with a much lower risk EPS. On the contrary, most SGAs come
with higher risk of metabolic side effects (hyperlipidemia, hyperglycemia, and weight gain),
although these may not be as concerning for short-term, temporary use. Anticholinergic effects
and sedation effects differ among various individual FGAs and SGAs. For example, haloperidol
has the lowest risk for anticholinergic effects compared to other FGAs and certain SGAs such as
clozapine.31,32 This is also the case for sedation, where haloperidol has lower risk for this side
effect compared to many SGAs such as quetiapine, olanzapine, clozapine, risperidone and
ziprasidone.31,32 In addition, all antipsychotics come with a “black box” warning from the FDA
of increased mortality in older adults with dementia.
Several studies included documentation and monitoring of adverse effects during the
trial. Several studies found no increase in adverse events while using antipsychotics while others
found some increased side effects. For example, Michaud et al27 documented no torsades de
pointes, EPS, or deaths related to dysrhythmia or QTc prolongation with quetiapine treatment.
Similarly, six other studies found no difference in treatment groups with placebo vs haloperidol
in regards to QTc prolongation, arrhythmias, or EPS.12,14,16,18-20 On the contrary, one study found
a trend toward longer QTc intervals than baseline in patients who received continuous IV
haloperidol (although not statistically significant).33 However the rate of abnormal QTc intervals
was the same between study groups (haloperidol vs dexmedetomidine).33 Another study found
that more patients were over sedated and required non-invasive mechanical ventilation due to
respiratory depression when given haloperidol versus dexmedetomidine.13 One study
documented that only patients who received haloperidol developed QTc prolongation, however
this was not statistically significant.34 A meta-analysis assessing 15 randomized controlled trials
found that patients who received antipsychotics for delirium treatment experienced more dry
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mouth and sedation compared to placebo, and those who received SGAs experienced less EPS
compared to haloperidol.26 In addition, another randomized controlled trial found more
somnolence in patients treated with quetiapine.28 When compared to dexmedetomidine, one
study found that haloperidol led to significant over sedation and respiratory depression.13
Due to concerns for mortality and adverse events in older adults, some studies lowered
the dose of antipsychotic for older patients. Michaud et al27 provided lower doses of quetiapine
in patients older than 65, and there were no differences in adverse effects between age groups.
The authors suggested that lower doses of quetiapine in the elderly are just as effective as higher
doses, and the drug remains safe without increased adverse effects.27 Girard el al11 lowered the
haloperidol and ziprasidone doses for patients older than age 70 to half of the dose given for
patients younger than age 70. However, adverse effect or efficacy were not stratified by these
two age groups in the data report. Given that the higher doses were not given to older patients in
these two studies, it’s difficult to make a true conclusion regarding efficacy and optimal dosing.
In addition, some studies specifically enrolled older adults and found similar results. Larsen et
al22 studied patients older than age 65 who underwent hip-replacement surgery and found that
pre- and post-operative olanzapine resulted in no significant medical complications. Likewise,
Wang et al16 administered continuous low-dose IV haloperidol (0.5 mg loading dose followed by
0.1 mg/hour continuous infusion) to patients older than age 65 in the ICU and found no
significant differences in QTc prolongation between groups. They concluded that the dosing
regimen was safe and effective for elderly patients.16
Antipsychotics compared to other agents
Several studies have investigated alternative agents for delirium in comparison to
antipsychotics. One of the major agents used for delirium, and more often found to be effective,
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is dexmedetomidine. Dexmedetomidine is a selective ɑ-2 agonist with anxiolytic, sedative, and
analgesic effects that is used for ICU and procedural sedation.13 Many studies have shown
preference of dexmedetomidine over antipsychotics in managing delirium in terms of
effectiveness for both prevention and treatment. One randomized-controlled trial34 compared
continuous infusions of dexmedetomidine and haloperidol for the prevention of delirium in
patients on non-invasive ventilation. Out of 90 ICU patients, the authors found that the patient
who received dexmedetomidine had a lower incidence of delirium, lower incidence of
endotracheal intubation, and shorter hospital and ICU length of stay compared to both
haloperidol and placebo.34 Haloperidol did not show decreased delirium incidence compared to
placebo, but it did result in shorter duration of non-invasive ventilation and hospital LOS.34
Another study investigated continuous IV haloperidol versus dexmedetomidine infusions
in patients who were unable to be extubated from mechanical ventilation due to need for high
doses of sedation needed for agitation or delirium.33 The group who received dexmedetomidine
were extubated sooner (19.9 hours vs. 42.5 hours, p = 0.016) with resolution of delirium.33 The
dexmedetomidine group also experienced a shorter ICU length of stay. The authors concluded
that dexmedetomidine was more effective than haloperidol in treating agitation and delirium in
intubated patients.33 However, due to limitations including a small sample size (n = 20), the
authors recommended against changes in practice solely based on these results.33
A non-randomized controlled trial13 including 132 non-intubated ICU patients with
delirium studied the use of dexmedetomidine for delirium refractory to haloperidol treatment. In
this study, 132 patients with delirium received IV haloperidol every 10-30 mins until reaching
Richmond Agitation-Sedation Score (RASS) of 0 to -2 or max dose 30 mg. The patients were
divided into responders and non-responders to haloperidol. The responder group continued to
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receive haloperidol that was adjusted to maintain optimal RASS. The non-responders were
changed to a dexmedetomidine infusion. The study found that agitation was refractory to
haloperidol in 34.8% of patients. Patients who received haloperidol alone had a seven-fold
longer recovery time and two-fold ICU length of stay. All patients who received
dexmedetomidine promptly achieved target RASS and had no treatment failure.13
One study35 compared the use of haloperidol versus morphine in the treatment of postoperative delirium. Among 53 patients with delirium after cardiac surgery, patients either
received IM haloperidol or IM morphine sulfate hourly to control delirium symptoms until a
target RASS was achieved. The authors found that the duration of delirium, ICU length of stay,
hospital mortality, and adverse effects were not significantly different between groups. However,
the patients who received morphine received less additive sedation and had higher achievement
of target RASS within two hours as compared to haloperidol. The authors concluded that the
potential anxiolytic effect in the morphine group allowed for a quicker response in reducing
agitation.35
Although benzodiazepines are another commonly used medication for the treatment of
ICU delirium,36 there are very few studies comparing benzodiazepines to antipsychotics in this
setting. Only one study of comparison was found, but the study population was patients with
advanced cancer and delirium at end of life. Those who received a combination of haloperidol
plus lorazepam experienced greater reduction in agitation and appeared more comfortable with
less rescue medications than those who only received haloperidol.37 Given the study population,
it is difficult to apply this study to other critically ill patients with delirium. It is possible that
there are not many studies available due to benzodiazepines being a strong risk factor for the
development of delirium in critically ill patients.38 One trial even found that increased plasma
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concentrations of lorazepam was associated with increased risk of delirium the next day.39
Additionally, a 2009 Cochrane Database review40 studied the efficacy of benzodiazepines in
hospitalized patients with delirium. Only one study met selection criteria, and the authors
concluded that there is insufficient evidence for the use of benzodiazepines in non-alcohol
related delirium.40
Current Clinical Practice Guidelines on Delirium Management
Several practice guidelines have been published over the years in efforts to guide
practitioners on clinical usage of pharmacologic agents for delirium using the available literature.
The most recent guidelines published in 2018 from the Society of Critical Care Medicine
(SCCM) recommend against routine use of pharmacologic agents such as antipsychotics for
delirium.44 They recommend against antipsychotics, among other drugs, for prevention of
delirium due to the lack of effectiveness in outcomes such as mortality and length of stay in the
literature.44 In addition, they recommend against the routine use of antipsychotic agents for
delirium treatment, but state that selective short term use may be beneficial for patients who
experience severe and distressing symptoms.44 Previous recommendations from 2013 also do not
advocate for the use of haloperidol or SGAs for the prevention of delirium or for the use of
haloperidol to shorten delirium duration.5 This recommendation is supported by the lack of highquality studies that have more substantial sample sizes and consistency among studies. The 2013
guidelines do state, however, that SGAs may reduce delirium duration.5 Despite some studies
showing benefit, the guidelines state studies are still needed to confirm the consideration of using
SGAs for delirium routinely.5 Previous SCCM guidelines from 2002 recommended haloperidol
for treating delirium, however this was changed in the new guidelines due to new evidence
grading standards.
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Other international guidelines also exist to guide delirium treatment. Swiss guidelines
from 2007 recommend the use of antipsychotics as the first line treatment for delirium “when
pharmacologic treatment seems appropriate,” such as for behavioral symptoms along with
treating precipitating factors and using nonpharmacologic approaches.41 German guidelines from
2010 provide a more broad and vague statement that some evidence exists for using neuroleptics
for either treatment or prevention of delirium.46 Guidelines from the United Kingdom in 2010
recommend short-term haloperidol if the patient is distressed or risk of harming themselves or
others and non-pharmacologic treatments were ineffective.42
Methods
A literature search was conducted using several databases available in the Augsburg
library. Databases used include PubMed, MEDLINE, Science Direct, Google Scholar and
UpToDate. Articles were also found by utilizing the reference lists of review articles and
searching among articles for commonly cited studies. Only articles in English were included.
Inclusion criteria for this review included studies on adult patients older than 18 years, patients in
the intensive care unit or post-operative, patients who were evaluated for delirium, and the
patients were given pharmacologic management for prevention or treatment of delirium
(particularly antipsychotics). Types of studies include randomized controlled trials, systematic
reviews, meta-analyses, prospective and retrospective observational studies, and clinical practice
guidelines. Search terms utilized include delirium, intensive care unit (ICU), critically ill,
agitation, prevention, treatment, management, pharmacologic, antipsychotic, benzodiazepine.
Discussion
Given the above literature review, it is clear that there is conflicting data concerning the
prophylaxis and treatment of delirium in critically ill patients. The multifactorial pathogenesis of
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delirium itself along with the unclear antipsychotic efficacy and safety in critically ill patients
creates uncertainty whether these drugs should be routinely used. As will be discussed, several
factors vary widely among studies on both prevention and treatment of delirium with
antipsychotics, making pooling results difficult and thus preventing the ability to make a
meaningful consensus for clinical practice.
Literature on the use of antipsychotics for delirium prophylaxis in critically ill patients
shows mixed results from various randomized-controlled trials and review papers. Among
individual trials, several found no improvement of either incidence or duration of delirium with
adding haloperidol as a prophylactic regimen.12,17,18 Among the studies that found no difference
in preventing delirium, there were several limitations to acknowledge. First, the sample sizes
were very small in two of the studies (142 participants in Page et al17 and 68 participants in AlQuadheeb et al18). In addition, each of these studies allowed varying degrees of rescue
medication for agitation such as open label antipsychotics,17 dexmedetomidine,12,18 and other
sedatives such as midazolam and propofol. The effect of these additional drugs on the results are
unknown. Finally, the patient populations of these studies included a wide range of medical,
surgical and trauma ICU patients. While this can simultaneously be considered a strength by
simulating a true ICU population, whether a more specific group would benefit from delirium
prophylaxis cannot be ruled out. The randomized controlled trial by Boogaard et al12 discussed
whether the lack of antipsychotic effectiveness was due to the higher extent of critical illness in
their population. Thus, they hypothesized whether a less critical population may see more benefit
from prophylaxis.12 However, an earlier retrospective study from the same author suggested that
those with higher delirium risk benefit more from antipsychotic prophylaxis. The PRE-DELIRIC
score used in the study directly relates to severity of illness by incorporating APACHE II score,
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infection, sepsis, urea concentration, metabolic acidosis, morphine and sedative use, and coma.
These conclusions are therefore highly conflicting and suggest that more high-quality
randomized-controlled trials are required to confirm whether or not prophylactic antipsychotics
benefit critically ill patients.
In contrast, most of the studies that found any statistical significance in outcomes were
studies involving antipsychotic prophylaxis in perioperative patient populations.16,22,23 Although
one of these studies utilized haloperidol,16 there were more studies with significant results that
included SGAs in the perioperative period.22,23 The areas of statistical significance in these
studies highlighted decreased incidence of delirium post-operatively.16,22,23 One advantage to
these studies is that each trial includes a single, somewhat specific study population (i.e. elderly
patients after non-cardiac surgery, elderly patients after joint replacement,22 and patients after
cardiac surgery.)16 While this makes it possible to apply to other similar populations, it is still
difficult to apply these results to a more generalized ICU population or among differing surgical
populations. One major limitation to two of these studies is the lack of baseline cognitive
screening pre-operatively to rule out pre-existing dementia that could affect these results.16,22
However, both studies conclude that the data remains valid as the randomization process
increases the likelihood of any patients with pre-existing cognitive dysfunction to be equal
among groups.16,22 Overall, these studies of patients in the perioperative state may be extremely
beneficial in guiding future studies to further confirm which patients may benefit from
prophylactic therapy. Replication of these results with more standardized design and drug dosing
would increase the strength of evidence to then better apply to clinical practice.
Systematic reviews and meta-analysis on prophylactic antipsychotic use show low quality
evidence, making it difficult to do meaningful meta-analysis and hard to compare studies.7 In
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accordance with the above individual trials, some meta-analyses showed significance in postoperative studies rather than in generalized ICU studies. Two meta-analyses found a risk
reduction for development of delirium when using perioperative antipsychotics.19,20 One study in
particular pointed out olanzapine and risperidone as superior to haloperidol in delirium
prevention.20 However, other meta-analyses found no effect of antipsychotics on delirium
(including one Cochrane Review).7,14 One major limitation of these review papers is the lack of
available studies and small sample sizes. Three meta-analyses only included 6 or less studies
while one systematic review included only 2 studies. The populations were widely variable
among some of the analyses but were slightly narrower in the reviews that included only postoperative studies. Similar to the individual trials above, the only meta-analyses that showed a
decrease in delirium incidence were with perioperative data. Although this includes slightly
similar populations in comparison to other studies, heterogeneity between the types of surgical
populations still remains. Thus, the ability to apply the positive results in perioperative reviews
to other ICU populations may not be desirable, especially considering the lack of efficacy shown
in reviews with a generalized ICU population.
After comparing and contrasting studies on antipsychotic prophylaxis, the question
following question remains: Which patients (if any) should receive antipsychotics for delirium
prophylaxis, and when should this occur? Given the difference in results between study
populations, one may consider whether antipsychotic prophylaxis has an increased efficacy in
specifically surgical critically ill patients. Again, due to the variability in studies and associated
limitations, the ability to assess the validity of this conclusion is difficult until further studies are
completed. A non-randomized study21 that found haloperidol prophylaxis beneficial selected
patients at highest risk for delirium, which is a key difference from other studies who select
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patients regardless of delirium risk. However, this study lacked randomization, placebo group,
and blinding, and it had statistically different population differences between the control and
intervention groups.35 Although the quality of this evidence is weaker due to study design, these
results could help shape future randomized controlled trials to help better identify which patients
may benefit the most from antipsychotic prophylaxis. Finally, incidence of delirium is more
highly affected than duration in many of the perioperative studies. This may suggest that when
antipsychotics are used as prophylaxis, the result is only effective in fully preventing delirium
development versus aiming to decrease severity or length of delirium. One could conclude that if
delirium develops despite using prophylaxis, the severity or length of delirium will likely be
unaffected by the prophylactic antipsychotic doses. This conclusion should be interpreted with
caution, as it is unknown whether the drug dosage and duration was too low to see an effect on
delirium duration in more severe cases.19 This concept then brings into question the next topic of
discussion: whether antipsychotic treatment reduces delirium duration after delirium has already
developed.
Similar to studies that investigate delirium prophylaxis, the studies evaluating
antipsychotic drugs for delirium treatment have a high level of variability in both study design
and results. Among individual trials evaluated, two of the studies27,28 found decreased delirium
duration when using quetiapine for delirium treatment. However, these two studies are both
limited by small sample size (n = 11328 and n = 36).27 The small sample sizes as well as variation
in study methods makes it unclear whether these results should translate into concrete
recommendations for clinical practice. Both of these studies used strict inclusion and exclusion
criteria, which resulted in the small sample sizes.27,28 While this can be seen as an advantage to
avoid inherent biases in the data, the small sample leaves these studies greatly underpowered and
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also difficult to apply to a more widely generalized ICU population. One of these studies was a
retrospective cohort design that lacked a formal treatment algorithm, which further lacks power
to draw strong conclusions about the data. On the other hand, one larger randomized controlled
trial (n = 566)11 did not find any reduction in delirium duration. They also used broader inclusion
criteria that can likely be more widely applied clinically yet cannot rule out if a specific subgroup
would have benefited from delirium treatment.11 Similar to the studies on delirium prophylaxis,
the current trials on delirium treatment with antipsychotics is promising for future research. The
strength of evidence for or against use of antipsychotics would increase if there were more welldesigned studies to replicate results of smaller studies.
Many of the systematic reviews and meta-analyses suggest that antipsychotics do not
reliably improve delirium duration when used for treatment.14,24,25 One of the meta-analyses26 did
find a benefit in antipsychotic treatment for delirium by decreasing delirium severity scores.
Similar to the previous discussion on reviews and meta-analyses for delirium prophylaxis, the
heterogeneity between studies hinders the ability to pool results to make a strong conclusion
about the data. Each of these reviews discuss limitations such as variability in pharmacologic
interventions, different outcomes evaluated, and the overall small number of studies available.
The high degree of heterogeneity calls for more standardization in study design, interventions,
and population criteria to be able to better compare data.24
While the studies evaluated for both delirium prophylaxis and treatment do not strongly
show a relationship between routine antipsychotic use and decreased delirium, some studies
suggest that it may be more efficacious for acute treatment of specific delirium symptoms. Some
studies have noted decreased agitation in patients who receive prophylactic haloperidol despite
no statistically significant decrease in delirium incidence or duration.32,33 While this may be due
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to sedating effects of antipsychotics, the decrease in agitation may support the use of
antipsychotics on an as needed basis versus routine use in some patients. However, a Cochrane
Database review from 2017 suggested that the evidence is weak for recommending haloperidol
for agitation despite haloperidol resulting in faster onset to sleep/sedation compared to placebo.43
In contrast, many clinical practice guidelines38,41,42 do suggest rescue use for patients in severe
distress secondary to delirium. Although the evidence may not be strong, the rescue use of
antipsychotics for distressed patients where nonpharmacologic efforts have failed is one
recommendation that is more consistent across the clinical guidelines. Therefore,
individualization of treatment based on clinical judgement will likely be the mainstay of practice
before more studies are available to confirm the benefit of rescue antipsychotic use in delirium.
Interestingly, the recommendations and conclusions drawn from literature greatly
juxtapose the documented clinical utilization of drugs such as antipsychotics in practice. In a
2018 multinational cohort study of 1260 ICU patients, haloperidol was the most commonly used
medication for delirium intervention with 46% of patients with delirium receiving haloperidol.11
Some older studies also suggest frequent use of antipsychotics and other agents to manage
delirium. A 2011 survey of 250 pharmacists showed that 76% said haloperidol was the first
treatment of choice followed by SGAs (14%) and benzodiazepines (10%).14 A 2009 audit of 174
patients in a single facility showed antipsychotic medications were used in most patients with
signs of delirium.12 However, the most current SCCM guidelines do not make a recommendation
regarding routine use of antipsychotics for either prophylaxis or treatment due to the low quality
evidence available in current literature.38 The strong discrepancy between the current strength of
literature and the apparent clinical practice preferences brings into question whether anecdotal
evidence is playing a part in the wide use of antipsychotics among providers. In addition, it will
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be interesting to see how these guidelines and practices might change in the future pending the
inclusion of newer studies.
Given the widely variable guidelines, literature findings, and clinical practice, what are
the next steps in interpreting these guidelines for best clinical practice? First may be to consider
the specific patient population and whether literature suggests an associated benefit or additional
risk. As previously discussed, much of the data that shows any benefit of using antipsychotics for
delirium prevention is in postoperative patients rather than a generalized critically ill or
mechanically ventilated population.16,22,23 Thus, it may be difficult to apply this benefit to other
patients with more critical conditions where an unknown benefit may not outweigh inherent
risks. Next, the risks and adverse effects of antipsychotics should be carefully considered.
Although many studies have demonstrated overall safety and few adverse events in critically ill
populations, these studies excluded patients with already prolonged QTc intervals. Therefore, it
is recommended to avoid antipsychotic medications for delirium in patients at high risk of
developing torsades de pointes (prolonged QTc interval or receiving other QTc-prolonging
medication).5 In addition, sedative effects of many antipsychotics may not be as desirable for
elderly patients or those at risk for respiratory depression. Therefore, careful patient selection in
terms of cardiac risk, older age, and other pertinent risk factors may be necessary when selecting
antipsychotic drugs. When weighing risks and benefits, the lack of improvement in other end
outcomes such as mortality and length of hospital stay should be considered when using
antipsychotics in clinical practice.
Finally, it is also important to consider alternate or adjunctive therapies that provide
minimal risk and likely high benefit as compared to antipsychotics. Nonpharmacologic
prevention and therapy via a multicomponent strategy (improving mobility, vision, hearing,
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cognitive stimulation and sleep) should be the first consideration for delirium management.38
Each of these measures provides minimal risk to the patient and may prevent the need for drugs
that pose additional risks. Another consideration, especially in post-operative populations is
adequate pain control to treat and prevent delirium, as demonstrated in one study.35 Although this
study is underpowered with a small sample size, the concept of adequate pain management is
typically an integral piece to post-operative care. It makes sense to optimize a therapy that is
already implemented, such as pain management, prior to adding additional and potentially
unnecessary medications such as antipsychotics. Other medications should also be reviewed for
deliriogenic properties, namely benzodiazepines. As previously noted, benzodiazepine use is
considered a risk factor for delirium development in critically ill patients and has minimal
literature to support its use over antipsychotics. It is very difficult to assign superiority to either
benzodiazepines or antipsychotics as there are very few studies comparing the two drug classes
in critically ill patients. Based on the information available, it is likely best to avoid
benzodiazepines in patients at high risk for non-alcohol related delirium.
Dexmedetomidine has shown increased efficacy over antipsychotics for delirium
treatment in many studies. However, more research is needed to further strengthen this
conclusion. The studies previously analyzed show many weaknesses, such as small sample sizes
and lack of randomization and blinding. Two of these studies conclude that the results are not yet
strong enough to be routinely integrated into practice until more high-quality studies are needed
to confirm results. Despite these limitations, the results of these studies may be promising
particularly for those where antipsychotics are less desirable due to risk for respiratory
depression. For example, the SCCM guidelines recommend using dexmedetomidine to aid in
agitation that may be preventing ventilator weaning and extubation.44 Considering that some of
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the studies are of lower quality, the decision whether to use dexmedetomidine over
antipsychotics would require weighing patient factors (e.g. risk for respiratory depression,
sedation needs, cardiac risk, etc.) against the drug characteristics (e.g. the adverse effect profile)
to administer the most appropriate therapy.
Conclusion
Overall, it appears that antipsychotics may reduce incidence of delirium in certain patient
populations as well as potentially decreasing duration when used as treatment. However, the
evidence that these agents reduce other risk outcomes such as mortality is lacking. The variation
in study populations and drug regimens along with the small sample sizes of studies greatly
impairs the ability to draw concrete conclusions regarding the use of antipsychotic medications
for delirium. Even so, organizations such as the SCCM have compiled this evidence into
recommendations for clinical practice, but actual clinical practice may not always adhere to the
available guidelines. This may reflect the lack of high-quality, consistent literature and be a
calling for additional studies to confirm or refute the validity of current practice. Given the lower
quality of evidence, when and if to use antipsychotics in a patient with delirium remains
somewhat uncertain. While routine use cannot yet be officially condoned, it does seem
reasonable to administer antipsychotic medication using one’s clinical judgment and pending the
individual patient situation. Factors to consider when deciding to administer “as needed” doses in
patients may include, but are not limited to: level of distress caused by delirium symptoms, the
risk of harming themselves or others, additional nonpharmacologic and pharmacologic options
that may be appropriate, and the risks associated with the drug itself (e.g. QTc prolongation and
excessive sedation).
Future research in this area is required to better establish the benefits and risks associated
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with antipsychotics and delirium. In particular, more large-scale randomized controlled trials
with consistency in drug dosing, patient population and selection criteria, and controlled
variables (other medications, non-pharmacologic treatments, etc.) are needed in order to allow
for stronger meta-analyses and the ability to draw overall conclusions. Although many studies
have shown benefit in areas such as reducing incidence and duration of delirium, it may be
difficult to implement routine use of antipsychotics if there is no significant improvement on
other important parameters such as mortality, hospital length of stay, or long-term comorbidities.
The future research of this topic has the potential to not only streamline current medical practice,
but to also improve the patient experience in the ICU by potentially reducing distress associated
with delirium.
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